Isoliquiritigenin inhibits apoptosis and ameliorates oxidative stress in rheumatoid arthritis chondrocytes through the Nrf2/HO-1-mediated pathway

Hung, Shih-Ya; Chen, Jen-Lung; Tu, Yuan-Kun; Tsai, Hsin-Yi; Lu, Pin-Hsuan; Jou, I.-Ming; Mbuyisa, Lulekiwe; Lin, Ming-Wei

doi:10.1016/j.biopha.2023.116006

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Preprint1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 8 publications

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

TRPV1 Regulates Proinflammatory Properties of M1 Macrophages in Periodontitis Via NRF2

Li,

Guo,

Zhan

et al. 2024

Inflammation

View full text Add to dashboard Cite

TRPV1 Regulates Proinflammatory Properties of M1 Macrophages in Periodontitis Via NRF2

Li,

Guo,

Zhan

et al. 2024

Inflammation

View full text Add to dashboard Cite

Isoliquiritigenin alleviates experimental autoimmune encephalomyelitis by modulating inflammatory and neuroprotective reactive astrocytes

Zhang,

Qu,

Song

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Tannic Acid-Based Biomimetic Nanomedicine with Pathological Reactive Oxygen Species-Responsive Cargo Release for Relieving Inflammation in Rheumatoid Arthritis

Zhao,

Wu,

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic disease characterized by immune cell infiltration and cartilage damage. The local lesion of RA shows severe oxidative stress and proinflammatory cytokine secretion. For drug therapy, the efficacy of agents, such as methotrexate (MTX), may be greatly limited, resulting from the low bioavailability, immune clearance, and toxic side effects. A nanocarrier (TA-PBA NPs) was developed with anti-inflammatory and antioxidant activities, combined with MTX to prepare nanomedicine (MTX NPs) for synergistic treatment of RA. Moreover, inspired by the biological functions homing to inflammation lesion of macrophages, the biomimetic nanomedicine camouflaged with macrophage membrane (MM@MTX NPs) was constructed. TA-PBA NPs could timely promote MTX release in response to the overaccumulated ROS to exhibit high anti-inflammatory and antioxidant activities for alleviating RA progression. The experimental results confirmed that MM@MTX NPs could significantly reduce the secretion of proinflammatory cytokines (TNF-α) while significantly increasing the typical anti-inflammatory cytokines (IL-10), promote the phenotype transformation of macrophages from M1 to M2, and upregulate the Nrf2-keap1 pathway-related proteins (HO-1 and NRF2) to positively regulate the local inflammation for effectively inhibiting RA development. Thus, MM@MTX NPs represent a possible candidate as a safe and efficient nanotherapy platform for RA management.

show abstract

Isoliquiritigenin inhibits apoptosis and ameliorates oxidative stress in rheumatoid arthritis chondrocytes through the Nrf2/HO-1-mediated pathway

Cited by 8 publications

References 43 publications

TRPV1 Regulates Proinflammatory Properties of M1 Macrophages in Periodontitis Via NRF2

TRPV1 Regulates Proinflammatory Properties of M1 Macrophages in Periodontitis Via NRF2

Isoliquiritigenin alleviates experimental autoimmune encephalomyelitis by modulating inflammatory and neuroprotective reactive astrocytes

Tannic Acid-Based Biomimetic Nanomedicine with Pathological Reactive Oxygen Species-Responsive Cargo Release for Relieving Inflammation in Rheumatoid Arthritis

Contact Info

Product

Resources

About